Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).

Détails

ID Serval
serval:BIB_511305A813BC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).
Périodique
American Journal of Cardiology
Auteur(s)
Wyszynski D.F., Waterworth D.M., Barter P.J., Cohen J., Kesäniemi Y.A., Mahley R.W., McPherson R., Waeber G., Bersot T.P., Sharma S.S., Nolan V., Middleton L.T., Sundseth S.S., Farrer L.A., Mooser V., Grundy S.M.
ISSN
0002-9149
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
95
Numéro
2
Pages
194-198
Langue
anglais
Résumé
Genetic Epidemiology of Metabolic Syndrome is a multinational, family-based study to explore the genetic basis of the metabolic syndrome. Atherogenic dyslipidemia (defined as low plasma high-density lipoprotein cholesterol with elevated triglycerides (<25th and >75th percentile for age, gender, and country, respectively) identified affected subjects for the metabolic syndrome. This report examines the frequency at which atherogenic dyslipidemia predicts the metabolic syndrome of the National Cholesterol Education Program Adult Treatment Panel III (ATP-III). One thousand four hundred thirty-six (854 men/582 women) affected patients by our criteria were compared with 1,672 (737 men/935 women) unaffected persons. Affected patients had more hypertension, obesity, and hyperglycemia, and they met a higher number of ATP-III criteria (3.2 +/- 1.1 SD vs 1.3 +/- 1.1 SD, p <0.001). Overall, 76% of affected persons also qualified for the ATP-III definition (Cohen's kappa 0.61, 95% confidence interval 0.59 to 0.64), similar to a separate group of 464 sporadic, unrelated cases (75%). Concordance increased from 41% to 82% and 88% for ages < or =35, 36 to 55, and > or =55 years, respectively. Affected status was also independently associated with waist circumference (p <0.001) and fasting glucose (p <0.001) but not systolic blood pressure (p = 0.43). Thus, the lipid-based criteria used to define affection status in this study substantially parallels the ATP-III definition of metabolic syndrome in subjects aged >35 years. In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors.
Mots-clé
Adolescent, Adult, Age Distribution, Aged, Australia/epidemiology, Canada/epidemiology, Cholesterol, HDL/blood, Female, Finland/epidemiology, Genetic Predisposition to Disease, Humans, Male, Metabolic Syndrome X/blood, Metabolic Syndrome X/diagnosis, Middle Aged, Sensitivity and Specificity, Severity of Illness Index, Switzerland/epidemiology, Triglycerides/blood, Turkey/epidemiology, United States/epidemiology
Pubmed
Web of science
Création de la notice
25/01/2008 15:10
Dernière modification de la notice
03/03/2018 17:10
Données d'usage